Search

Author/Creator Spiliopoulou, P.

2. 192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. (December 2022)

Authors:
Di Giacomo, A.M.; Santangelo, F.; Amato, G.; E. Simonetti, ; Graham, J.; Lahn, M.; van der Veen, L.; Hammett, T.; Pickering, C.A.; Durini, M.; Ziyang, T.; Lakshmikanth, T.; Brodin, P.; Occhipinti, M.; Simonelli, M.; Carlo-Stella, C.; Santoro, A.; Spiliopoulou, P.; Evans, T.R.J.; Maio, M.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 34TiP Prospective analysis of intestinal microbiome and autoimmune panels as predictors of toxicity in immunoncology patients (INSPECT-IO Study). (December 2022)

Authors:
Salawu, A.T.; Genta, S.; Spiliopoulou, P.; Yee, N.; M. Ye, ; Ly, L.; Taylor, R.; Vornicova, O.; Abdul Razak, A.R.; Bedard, P.L.; Wang, L.; Siu, L.L.; Coburn, B.; Spreafico, A.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗